REPATHA (EVOLOCUMAB) FOUR-YEAR OPEN-LABEL FOLLOW-UP STUDY PUBLISHED IN JAMA CARDIOLOGY Long-Term Study Identified No New Safety Concerns | Amgen AB
JAMA Cardiology - In this 12-month, placebo-controlled RCT of 26 well-treated persons with HIV without known CVD, eplerenone was associated with a significant reduction in arterial inflammation. https://ja.ma/49R22db | Facebook
![JAMA Cardiology Viewpoint article focuses on COVID-19 and cardiovascular aging science | National Institute on Aging JAMA Cardiology Viewpoint article focuses on COVID-19 and cardiovascular aging science | National Institute on Aging](https://www.nia.nih.gov/sites/default/files/styles/inline_right/public/2020-04/heart-medication-blood-pressure-equipment-inline-resized-compressor.jpg)
JAMA Cardiology Viewpoint article focuses on COVID-19 and cardiovascular aging science | National Institute on Aging
JAMA Cardiology on LinkedIn: The AWARE Trial tested an augmented WACA in patients with paroxysmal AF. A…
![Work by the Division of Research Makes Top JAMA Lists for 2018 - Kaiser Permanente Division of Research Work by the Division of Research Makes Top JAMA Lists for 2018 - Kaiser Permanente Division of Research](https://divisionofresearch.kaiserpermanente.org/wp-content/uploads/2019/01/2018-JAMA-Network-Top-Articles-Lists-w-DOR-1024x1024.png)